SG11201907358RA - Intrasite administration and dosing methods and pharmaceuticals for use therein - Google Patents

Intrasite administration and dosing methods and pharmaceuticals for use therein

Info

Publication number
SG11201907358RA
SG11201907358RA SG11201907358RA SG11201907358RA SG11201907358RA SG 11201907358R A SG11201907358R A SG 11201907358RA SG 11201907358R A SG11201907358R A SG 11201907358RA SG 11201907358R A SG11201907358R A SG 11201907358RA SG 11201907358R A SG11201907358R A SG 11201907358RA
Authority
SG
Singapore
Prior art keywords
intrasite
international
administration
drugs
pharmaceuticals
Prior art date
Application number
SG11201907358RA
Inventor
Terrence Holekamp
Michael Kelly
Lawrence Lenke
Original Assignee
Hkl Medical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hkl Medical Llc filed Critical Hkl Medical Llc
Publication of SG11201907358RA publication Critical patent/SG11201907358RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D3/00—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
    • B01D3/14—Fractional distillation or use of a fractionation or rectification column
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT 0111111010 0111 °nolo DID IH mo IH Imio oimIE (10) International Publication Number WO 2018/148455 Al (51) International Patent Classification: A61L 27/00 (2006.01) A61L 15/00 (2006.01) A61L 26/00 (2006.01) (21) International Application Number: PCT/US2018/017486 (22) International Filing Date: 08 February 2018 (08.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/456,639 08 February 2017 (08.02.2017) US 62/456,642 08 February 2017 (08.02.2017) US (71) Applicant: HKL MEDICAL, LLC [US/US]; 1965 Broad- way, Apt. 22AB, New York, NY 10023 (US). (72) Inventors: HOLEKAMP, Terrence, Fletcher; 1529 Grandview Place, East Seattle, WA 98112 (US). KEL- LY, Michael, Patrick; 4367 McPherson Avenue, Saint Louis, MO 63108 (US). LENKE, Lawrence, Gerard; 1965 Broadway, Apt. 22AB, New York, NY 10023 (US). (74) Agent: GIORDANO, David et al.; Giordano Law LLC, 1 Boston Place, Suite 2600, Boston, MA 02108 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN (57) : A new method of targeted intrasite drug administration to wounds offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing intrasite medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large intrasite doses increase risk of toxicity from impurities allowed in drugs given by other routes. Pharmacodynamic parameters make certain drugs advantageous as intrasite agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an intrasite medication. Other drugs, including but not limited to rifaximin, possess similar pharmacodynamics and may be useful intrasite pharmaceuticals, delivered alone or in combination with other drugs, carriers, or materials. All of these attributes are advantages over traditional administration methods.
SG11201907358RA 2017-02-08 2018-02-08 Intrasite administration and dosing methods and pharmaceuticals for use therein SG11201907358RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762456639P 2017-02-08 2017-02-08
US201762456642P 2017-02-08 2017-02-08
PCT/US2018/017486 WO2018148455A1 (en) 2017-02-08 2018-02-08 Intrasite administration and dosing methods and pharmaceuticals for use therein

Publications (1)

Publication Number Publication Date
SG11201907358RA true SG11201907358RA (en) 2019-09-27

Family

ID=63038960

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907358RA SG11201907358RA (en) 2017-02-08 2018-02-08 Intrasite administration and dosing methods and pharmaceuticals for use therein

Country Status (8)

Country Link
US (6) US20180221296A1 (en)
EP (1) EP3579891A4 (en)
JP (1) JP2020506974A (en)
CN (1) CN110997020A (en)
AU (1) AU2018219299A1 (en)
CA (1) CA3053122A1 (en)
SG (1) SG11201907358RA (en)
WO (1) WO2018148455A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190221300A1 (en) * 2018-01-18 2019-07-18 George James Pate Method for dispensing medication
US20200368483A1 (en) * 2019-05-24 2020-11-26 Stamford Devices Ltd. Design of aerosol chamber and interface to optimize inhaled dose with neonatal cpap device
BR112021024933A2 (en) * 2019-06-11 2022-02-08 Animal Ethics Pty Ltd Topical drug delivery formulation and composition, method of delivering at least one drug, use of at least one drug and drug delivery formulation, method of manufacturing a topical drug delivery composition, and, methods of providing and administering relief of pain
CN115702016A (en) * 2020-05-05 2023-02-14 呼吸医疗技术有限公司 Fluid dispensing device
US11745579B2 (en) 2021-04-05 2023-09-05 Eaton Cummins Automated Transmission Technologies Llc Full power-shift hybrid transmission and hybrid torquefill in automated manual transmission
CN116983541B (en) * 2023-09-28 2023-12-15 中国人民解放军总医院第四医学中心 Wound repair device capable of rapidly replacing growth factor gel application

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122717C (en) * 1991-11-08 2003-07-15 David C. Anderson Hemoglobins as drug delivery agents
AU3326693A (en) * 1991-12-12 1993-07-19 Scripps Research Institute, The Bifunctional antithrombotic molecules and antithrombotic polypeptides
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6046160A (en) * 1999-07-22 2000-04-04 Deroyal Industries, Inc. Composition and method for enhancing wound healing
DE19962470A1 (en) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Use of chemotherapy drugs
US20040151765A1 (en) * 2001-09-18 2004-08-05 Ritchie Branson W. Methods and compositions for wound management
CA2323382C (en) * 2000-10-17 2004-04-13 Pharma Mag Inc. Wound dressing
AU2002367083B2 (en) * 2001-12-21 2008-02-28 Coloplast A/S A wound care device
US7125402B1 (en) * 2002-05-29 2006-10-24 Surgimark, Inc. Surgical drain
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
US7816140B2 (en) * 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US7517536B2 (en) * 2005-11-25 2009-04-14 Feng Chia University Antimicrobial compositions and wound dressings
WO2007109357A2 (en) * 2006-03-21 2007-09-27 Teva Pharmaceutical Industries Ltd. Controlled release formulation of tolterodine
CN101534840A (en) * 2006-08-02 2009-09-16 萨利克斯药品公司 Methods for the treatment of radiation proctosigmoitis
US20110237496A1 (en) * 2008-09-10 2011-09-29 Ilana Nathan Antinecrotic activity of alpha 1-antitrypsin
JP5936536B2 (en) * 2009-03-16 2016-06-22 ユニバーシティー オブ メンフィス リサーチ ファウンデーション Compositions and methods for delivering agents to wounds
US8998854B2 (en) * 2010-01-28 2015-04-07 Warsaw Orthopedic, Inc. Catheter devices and drainage systems for delivering therapeutic agents
ES2640756T3 (en) * 2010-10-22 2017-11-06 Dr. Reddy's Laboratories Sa. Use of stable viscous phospholipid deposits to treat wounds
ES2748519T3 (en) * 2010-12-08 2020-03-17 Convatec Technologies Inc Wound exudate system accessory
US9156896B2 (en) * 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
WO2015123501A1 (en) * 2014-02-14 2015-08-20 University Of Memphis Research Foundation Compositions and methods for delivering an agent to a wound
US9241971B1 (en) * 2014-07-18 2016-01-26 Kurobe, Llc Topical vancomycin formulation and methods of use
US10058506B2 (en) * 2014-11-14 2018-08-28 Brown University Tunable anti-microbial loaded hydrogels

Also Published As

Publication number Publication date
EP3579891A1 (en) 2019-12-18
WO2018148455A1 (en) 2018-08-16
US20180221296A1 (en) 2018-08-09
US20190000772A1 (en) 2019-01-03
EP3579891A4 (en) 2021-01-06
US20180344659A1 (en) 2018-12-06
US20190008794A1 (en) 2019-01-10
JP2020506974A (en) 2020-03-05
AU2018219299A1 (en) 2019-09-19
US20190000771A1 (en) 2019-01-03
CA3053122A1 (en) 2018-08-16
CN110997020A (en) 2020-04-10
US20190008793A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
SG11201907358RA (en) Intrasite administration and dosing methods and pharmaceuticals for use therein
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201806340YA (en) Zika virus vaccine
SG11201811432WA (en) Rna for cancer therapy
SG11201903946SA (en) Devices and methods for slurry generation
SG11201910191RA (en) A peptide capable of forming a gel for use in tissue engineering and bioprinting
SG11201407512VA (en) High-concentration monoclonal antibody formulations
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908060PA (en) Wound healing medicament
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201809788VA (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201906557UA (en) Novel stable formulation for fxia antibodies